<DOC>
	<DOCNO>NCT02531854</DOCNO>
	<brief_summary>- Open label - Enrollment order confirmation eligibility HPV+ tumor status - Prospective stratification base 3 factor , epidermal growth factor receptor ( EGFR ) mutation status , performance status first-line induction chemotherapy outcome ; - Randomization ( 2:1 ratio ) : ( 82 patient receive combination pemetrexed plus ADXS11-001 vs. 42 patient receive pemetrexed alone ) - Treatment Arm : Pemetrexed plus ADXS11-001 immunotherapy - Control Arm : Pemetrexed - Positive control : pemetrexed chemotherapy</brief_summary>
	<brief_title>A Study Pemetrexed Maintenance With Without ADXS11-001 Immunotherapy Patients With Human Papillomavirus Positive ( HPV+ ) , NSCLC Following First-Line Induction Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Male female patient , ≥ 20 year age 2 . Patients NSCLC 3 . Patients whose disease either respond progress follow 46 cycle firstline induction chemotherapy . 4 . Patients documented/confirmed intratumor positivity HPV 5 . Patients major exist comorbidities medical condition preclude administration therapy , opinion Investigator 6 . Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 7 . Patients use contraception study 8 . Patients ability understand give write informed consent participation trial 1 . Women pregnant breast feed 2 . Patients histologically cytologicallyconfirmed squamous cellclassified NSCLC 3 . Patients disease progression follow firstline induction chemotherapy 4 . Patients know active uncontrolled central nervous system ( CNS ) leptomeningeal metastases 5 . Patients active second primary malignancy history another malignancy 6 . Patients inadequate recovery acute toxicity associate prior antineoplastic therapy , include ≥ Grade 2 neuropathy 7 . Patients inadequate recovery previous surgical procedure , patient undergo major surgical procedure within 4 week prior start study treatment 8 . Patients evidence inadequate organ function define protocol 9 . Patients know allergy follow antibiotic : ampicillin , trimethoprimsulfamethoxazole 10 . Patients know allergy antiemetic medication and/or nonsteroidal antiinflammatory drug ( e.g. , ibuprofen , naproxen , celecoxib ) 11 . Patients history severe hypersensitivity reaction pemetrexed disodium ( Alimta® equivalent ) , excipients use formulation 12 . Patients history autoimmune disorder require systemic treatment within past 3 month , document history clinically severe autoimmune disease syndrome require systemic steroid immunosuppressive agent 13 . Patients known immunodeficiency include patient : HIV infection , undergone previous organ transplantation require immunosuppressive therapy longterm immunosuppressive therapy reason 14 . Patients interstitial lung disease active , noninfectious pneumonitis , active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) 15 . Patients active infection require systemic therapy , prior dose study drug 16 . Patients lifethreatening illness , uncontrolled medical condition ( e.g. , elevated troponin creatinine ; uncontrolled diabetes ) , significant organ system dysfunction , clinically significant laboratory abnormality , opinion Investigator would either compromise patient 's safety interfere evaluation study treatment 17 . Patients psychiatric disorder , substance abuse disorder , alter mental status would preclude understand informed consent process and/or completion necessary studyrelated evaluation 18 . Patients history current evidence condition , therapy , laboratory abnormality might : confound result trial , interfere patient 's participation trial , suggest participation trial best interest patient , opinion treat investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>